Streamlined liver cancer treatment tested in new study

NCT ID NCT06979219

Recruiting now Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a faster version of radioembolization for people with small liver cancers (5 cm or less). Normally, doctors do a pre-treatment scan to check for lung risks, but this trial skips that step for carefully selected patients. The goal is to see if the simplified approach is still safe and effective at destroying tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Yttrium-90 resin microspheres (SIR-Spheres)
What this could lead to: If successful, this could make liver cancer treatment faster and simpler by safely skipping an extra imaging step.
What could go wrong: This is an early registry study with only 146 participants, so results may not apply to all patients. There is a risk that skipping the pre-scan could miss lung shunt issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

National Cancer Center
RECRUITING

Goyang, South Korea
Samsung Medical Center
NOT_YET_RECRUITING

Seoul, South Korea
Seoul National University Hospital
RECRUITING

Seoul, South Korea
Severance hospital
NOT_YET_RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.